Literature DB >> 12517687

Decreased plasma adiponectin concentration in patients with essential hypertension.

Marcin Adamczak1, Andrzej Wiecek, Tohru Funahashi, Jerzy Chudek, Franciszek Kokot, Yuji Matsuzawa.   

Abstract

Adipocytes secrete several biologically active substances that are presumed to be involved in obesity-related hypertension. There are no reports that deal with the relationship between plasma adiponectin concentration and blood pressure (BP). To evaluate the role of adiponectin in essential hypertension 33 patients with essential hypertensive (EHP) (12 women, 21 men) and 33 body mass index-matched normotensive healthy subjects (NHS) (13 women, 20 men) were studied. In EHP plasma adiponectin concentration was significantly lower than in NHS (9.1 +/- 4.5 v 13.7 +/- 5.2 microg/mL, respectively). In all subjects a significant negative correlation was found between plasma adiponectin concentration and mean, systolic, and diastolic BP, suggesting that adiponectin contributes to the clinical course of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517687     DOI: 10.1016/s0895-7061(02)03197-7

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  75 in total

1.  Adipose tissue as regulator of vascular tone.

Authors:  Charlotte Boydens; Nele Maenhaut; Bart Pauwels; Kelly Decaluwé; Johan Van de Voorde
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

2.  Plasma adiponectin and insulin resistance in new onset hypertension.

Authors:  Teoman Dogru; Alper Sonmez; Ilker Tasci; M Ilker Yilmaz; Selim Kilic; Taner Ozgurtas; Tayfun Eyileten; M Kemal Erbil; I Hakki Kocar
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

3.  Decreased serum adiponectin in adolescents and young adults with familial primary hypercholesterolemia.

Authors:  Lian-Yu Lin; Chiau-Suong Liau; Wei-Shiung Yang; Ta-Chen Su
Journal:  Lipids       Date:  2005-02       Impact factor: 1.880

4.  Body composition is related to increase in plasma adiponectin levels rather than training in young obese men.

Authors:  Taketaka Hara; Hiroshi Fujiwara; Hayato Nakao; Tatsuya Mimura; Takahiro Yoshikawa; Shigeo Fujimoto
Journal:  Eur J Appl Physiol       Date:  2005-06-08       Impact factor: 3.078

Review 5.  Current and novel approaches to the drug therapy of obesity.

Authors:  Jean-Philippe Chaput; Angelo Tremblay
Journal:  Eur J Clin Pharmacol       Date:  2006-08-26       Impact factor: 2.953

6.  Genetic determination of adiponectin and its relationship with body fat topography in multigenerational families of African heritage.

Authors:  Iva Miljkovic-Gacic; Xiaojing Wang; Candace M Kammerer; Clareann H Bunker; Victor W Wheeler; Alan L Patrick; Lewis H Kuller; Rhobert W Evans; Joseph M Zmuda
Journal:  Metabolism       Date:  2007-02       Impact factor: 8.694

7.  Up-regulation of rat adipose tissue adiponectin gene expression by long-term but not by short-term food restriction.

Authors:  Jacek Turyn; Justyna Korczynska; Malgorzata Presler; Ewa Stelmanska; Elzbieta Goyke; Julian Swierczynski
Journal:  Mol Cell Biochem       Date:  2008-03-08       Impact factor: 3.396

8.  Estimating the contributions of rare and common genetic variations and clinical measures to a model trait: adiponectin.

Authors:  S Sandy An; Nicholette D Palmer; Anthony J G Hanley; Julie T Ziegler; W Mark Brown; Steven M Haffner; Jill M Norris; Jerome I Rotter; Xiuqing Guo; Y-D Ida Chen; Lynne E Wagenknecht; Carl D Langefeld; Donald W Bowden
Journal:  Genet Epidemiol       Date:  2012-10-02       Impact factor: 2.135

9.  Serum adiponectin levels and lifestyle factors in Japanese men.

Authors:  Kazuhiko Kotani; Naoki Sakane; Kyoko Saiga; Masahiko Kato; Katsunori Ishida; Yosuke Kato; Youichi Kurozawa
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

Review 10.  APPL1: role in adiponectin signaling and beyond.

Authors:  Sathyaseelan S Deepa; Lily Q Dong
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-14       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.